MedTrace Logo

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

NCT06725498 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-10

No results posted yet for this study

Summary

This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection. For those patients who remain non-resectable, a tailored treatment plan is proposed, consisting of arterial infusion chemotherapy in conjunction with radiotherapy, succeeded by a series of immune checkpoint inhibitors. The efficacy and safety of this integrated therapeutic strategy are meticulously assessed, with the goal of enhancing survival outcomes for patients with T4bNanyM0 HNSCC.

Conditions

Interventions

DRUG

Tislelizumab-jsgr

200mg, Q3W

DRUG

Cisplatin

60-75 mg/㎡, Q3W

DRUG

Albumin-Bound Paclitaxel

260 mg/㎡, Q3W

RADIATION

Radiotherapy

Radical Radiotherapy or adjuvant Radiotherapy per guidelines.

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2026-11-30
Completion
2029-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06725498 on ClinicalTrials.gov